Solvay extends Quintiles partnership

By staff reporter

- Last updated on GMT

Related tags: Medicine, Quintiles

Solvay Pharmaceuticals said it has decided to renew its clinical
development contract with Quintiles for further five years.

Under the existing partnership the two firms have worked together since 2001, completing three Phase III clinical testing programs, moving two compounds from Phase II to Phase III and produced conclusive Phase II data that resulted in the termination of two other programs. "Using Quintiles' global infrastructure and experts we've advanced projects at a much faster rate than we could have achieved alone, and with greater flexibility,"​ said Werner Cautreels, CEO of Solvay. "Over the next five years we aim to achieve even higher levels of value in terms of efficiency, speed and cost-savings."​ No other terms of the deal were released by the Belgian pharma firm, who specialises developing drugs for areas of unmet medical need in the fields of neuroscience, cardio-metabolic, influenza vaccines and gastroenterology.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars